Literature DB >> 22918696

Surgery for relapsed ovarian cancer: when should it be offered?

Philipp Harter1, Florian Heitz, Andreas du Bois.   

Abstract

Whilst cytoreductive surgery is the mainstay treatment for primary ovarian cancer, its role in relapse is still unclear. Surgery in platinum-sensitive recurrent ovarian cancer might be beneficial if it results in complete resection of the disease. Clinical scores could help to identify suitable patients. Level I evidence is still missing; however, two randomized trials (DESKTOP III and GOG 213) are ongoing.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22918696     DOI： 10.1007/s11912-012-0260-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  35 in total

1.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

Authors:  S M Eisenkop; R L Friedman; N M Spirtos
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

Review 2.  Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Authors:  Philipp Harter; Felix Hilpert; Sven Mahner; Florian Heitz; Jacobus Pfisterer; Andreas du Bois
Journal:  Expert Rev Anticancer Ther       Date:  2010-01       Impact factor: 4.512

3.  A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.

Authors:  Wen-Juan Tian; Dennis S Chi; Jalid Sehouli; Claes G Tropé; Rong Jiang; Ali Ayhan; Gennaro Cormio; Yan Xing; Georg-Peter Breitbach; Elena Ioana Braicu; Catherine A Rabbitt; Halldis Oksefjell; Christina Fotopoulou; Hans-Gerd Meerpohl; Andreas du Bois; Jonathan S Berek; Rong-Yu Zang; Philipp Harter
Journal:  Ann Surg Oncol       Date:  2011-07-06       Impact factor: 5.344

4.  Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.

Authors:  Jalid Sehouli; Konstantinos Savvatis; Elena-Ioana Braicu; Sven-Christian Schmidt; Werner Lichtenegger; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2010-11       Impact factor: 3.437

5.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

6.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

Authors:  Dennis S Chi; Kristina McCaughty; John P Diaz; Jae Huh; Sarah Schwabenbauer; Amanda J Hummer; Ennapadam S Venkatraman; Carol Aghajanian; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

7.  Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

Authors:  Philipp Harter; Zelal M Muallem; Christine Buhrmann; Dietmar Lorenz; Christine Kaub; Rita Hils; Stefan Kommoss; Florian Heitz; Alexander Traut; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2011-03-17       Impact factor: 5.482

8.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

9.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

10.  Secondary cytoreduction for ovarian cancer following cisplatin therapy.

Authors:  R A Segna; P R Dottino; J P Mandeli; K Konsker; C J Cohen
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544
View more
  5 in total

1.  Secondary cytoreduction versus chemotherapy alone in the treatment of patients with recurrent ovarian cancer: is a randomized trial worthwhile?

Authors:  Paolo Sammartino; Daniele Biacchi; Marialuisa Framarino
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

2.  Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.

Authors:  Takeo Minaguchi; Toyomi Satoh; Koji Matsumoto; Manabu Sakurai; Hiroyuki Ochi; Mamiko Onuki; Akinori Oki; Hiroyuki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2015-10-16       Impact factor: 3.402

3.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

4.  The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial.

Authors:  Hongyuan Gu; Rui Zhou; Jing Ni; Xia Xu; Xianzhong Cheng; Yan Li; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2020-06-16       Impact factor: 4.234

5.  Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients.

Authors:  Karl Reinhard Aigner; Emir Selak; Sabine Gailhofer; Kornelia Aigner
Journal:  Indian J Surg Oncol       Date:  2019-04-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.